Cytodyn Inc (CYDY)

[JPG77]

CITIBANK COVERAGE

Sharing from another site:

[1] Citibank is one of the biggest investment banks and they came out with a Buy rating on CYDY on 11/16/21.

[2] It’s hard to interpret the report because there is no analyst assigned to it or any context to the positive rating.

[3] Following OTC stocks is not something Citibank would do without a reason. It’s very likely that they want to broker a deal between CYDY and big pharma and if the stock were to dip below $1.00 it could throw a wrinkle in their plans which explains the timing of their rating.

[4]. There also seems to be some significant speculation in the media that CYDY is a potential joint venture partner in COVID-19 or even a buyout candidate. That chatter is hard to ignore when it’s real. Investors know Merck is in trouble with their COVID-19 pipeline and prepping the fields. Those types of deals would likely mean a double digit stock price for CYDY. Adding to the speculation is the fact that CytoDyn isn’t shying away from admitting that they are in talks. They cannot discuss the extent of the discussions due to confidentiality.

[5]. This Citibank coverage could also be due to the large retail following of the stock.

[6]. Regardless of the reason, what is certain is that Citibank has a top notch compliance and due diligence team that wouldn’t even dream of touching a company that has a DOJ or SEC investigation waiting in the wings—they only want to work with and cover the cream of the crop.

[7]. This coverage may finally give the longs something to crow about to debunk the shorts ideas that the DOJ was coming after the company when in reality they may have actually been investigating the 13-D group and their admitted violations. Citigroup (NYSE: C) has incredible access when it comes to these types of situations and it’s rare that they would step on a landmine.